Northeast Financial Consultants’s Charles River Laboratories CRL Stock Holding History

Northeast Financial Consultants’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,073	Closed	-$418K	–	299
2023 Q1	$418K	Hold	2,073	–	–	0.03%	212
2022 Q4	$452K	Hold	2,073	–	–	0.03%	198
2022 Q3	$408K	Buy	2,073 +279	+16%	+$60.2K	0.03%	218
2022 Q2	$384K	Buy	1,794 +312	+21%	+$76.2K	0.03%	227
2022 Q1	$421K	Buy	1,482 +385	+35%	+$119K	0.02%	250
2021 Q4	$413K	Buy	+1,097	New	+$426K	0.02%	244

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Northeast Financial Consultants's CRL Position: Q2 2023 in Review

Northeast Financial Consultants sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 2,073 shares — an estimated $418K sold.

Northeast Financial Consultants first reported a position in CRL in Q4 2021 and held it in 6 quarters. The position peaked at $452K in Q4 2022. 612 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

Northeast Financial Consultants reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
Northeast Financial Consultants sold 2,073 Charles River Laboratories shares in Q2 2023, an estimated $418K.
Northeast Financial Consultants first reported a position in Charles River Laboratories in Q4 2021 and held it in 6 quarters.
Northeast Financial Consultants's Charles River Laboratories position peaked at $452K in Q4 2022.
612 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Northeast Financial Consultants's 13F filing for Q2 2023, filed 8 Aug 2023.